Predictive Bio-Markers
At HCRI, we’re committed to pushing the boundaries of predictive biomarker research to further refine the precision of cancer treatment
Predictive Biomarkers Research
In the rapidly evolving world of oncology, predictive biomarkers serve as the key to unlocking personalized cancer treatments. They provide us with a critical understanding of a patient’s specific disease characteristics, informing treatment plans and predicting treatment responses. At HCRI, we’re committed to pushing the boundaries of predictive biomarker research to further refine the precision of cancer treatment
Our Approach and Focus
Our team of scientists tirelessly investigates the molecular characteristics of different cancers, aiming to identify and validate biomarkers that predict the response to radiotherapy. By understanding how specific biomarker profiles interact with various treatments, we can tailor our approach to meet individual patient needs
We also delve into the realms of genomics, proteomics, and metabolomics, seeking to understand the comprehensive biological picture that influences cancer behavior and response to treatment. As we make strides in this field, we inch closer to our ultimate goal – targeted, effective, and less toxic cancer treatment
Integrating Predictive Biomarkers into Precision Radiotherapy
Biomarkers don’t just predict how a patient might respond to treatment, they also contribute to shaping the treatment. Our work in predictive biomarker research interweaves with our efforts in precision radiotherapy. By identifying which patients are likely to respond best to radiotherapy, we can guide the decision-making process, adjusting treatment protocols for optimal outcomes.
Additionally, our work extends to studying the effects of radiotherapy on biomarker expression and the development of resistance, contributing to the refinement of treatment strategies over time.
Research Collaboration for a Brighter Future
This endeavor requires collaboration. We engage in multi-disciplinary partnerships, both within and outside of HCRI, to advance our understanding of predictive biomarkers. Our shared goal is clear: to harness the power of biomarkers in predicting treatment responses, ultimately improving survival rates and the quality of life for cancer patients worldwide
